Aptar Pharma enters into exclusive agreement with Pulmotree for their NPLI inhaler platform

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has entered into an exclusive collaboration agreement with Pulmotree to lead the development and promotion of their Kolibri Non-Propellant Liquid Inhaler (NPLI) platform. As part of the agreement, Aptar Pharma will provide PULMOTREE with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri NPLI Platform Technology with Aptar’s suite of comprehensive services.

Non-Propellant Liquid Inhalers encompass nebulizers and soft-mist inhalers, and are being developed as an alternative to propellant-based systems. PULMOTREE’s Kolibri utilizes a robust breath-triggered Vibrating Mesh aerosolization engine with unique breath-guidance capabilities to enhance targeted lung deposition.

Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, said, “With this partnership, Aptar and PULMOTREE can provide a unique offer to the market to tune and tailor both formulation and delivery system seamlessly, and support drug development, to enable intuitive and efficient delivery in the hands of patients.”